ABCC1 and cancer: To overcome multidrug resistance in cancer patients, pyrrolo[2,3-d]pyrimidines and purine derivatives with high lipophilicity and molecular weight were developed as potent and selective inhibitors of multidrug resistance-associated protein 1 (MRP1, ABCC1) associated with non-response to chemotherapy in different cancers [39].